UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 207

Sortiert nach

Molecular Pathways: ROS1 Fusion Proteins in Cancer

Clinical cancer research, 2013-08, Vol.19 (15), p.4040-4045

2013

Link zum Volltext

Verfügbarkeit prüfen

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

Nature reviews. Clinical oncology, 2019-06, Vol.16 (6), p.341-355

2019

Link zum Volltext

Verfügbarkeit prüfen

TRKing down an old oncogene in a new era of targeted therapy

Cancer discovery, 2015-01, Vol.5 (1), p.25-34

2015

Link zum Volltext

Verfügbarkeit prüfen

Treating ALK-positive lung cancer--early successes and future challenges

Nature reviews. Clinical oncology, 2012-05, Vol.9 (5), p.268-277

2012

Link zum Volltext

Verfügbarkeit prüfen

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

Nature medicine, 2018-05, Vol.24 (5), p.638-646

2018

Link zum Volltext

Verfügbarkeit prüfen

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

International journal of radiation oncology, biology, physics, 2014-03, Vol.88 (4), p.892-898

2014

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1474-1482

2018

Link zum Volltext

Verfügbarkeit prüfen

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Clinical cancer research, 2018-07, Vol.24 (14), p.3334-3347

2018

Link zum Volltext

Verfügbarkeit prüfen

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-08, Vol.34 (24), p.2814-2819

2016

Link zum Volltext

Verfügbarkeit prüfen

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung Cancer

Clinical cancer research, 2012-09, Vol.18 (17), p.4570-4579

2012

Link zum Volltext

Verfügbarkeit prüfen

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2758-2770

2018

Link zum Volltext

Verfügbarkeit prüfen

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2012-12, Vol.7 (12), p.1807-1814

2012

Link zum Volltext

Verfügbarkeit prüfen

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

PloS one, 2013-12, Vol.8 (12), p.e82236

2013

Link zum Volltext

Verfügbarkeit prüfen

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Clinical cancer research, 2021-03, Vol.27 (5), p.1463-1475

2021

Link zum Volltext

Verfügbarkeit prüfen

Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor

Seminars in oncology, 2014-02, Vol.41 (1), p.110-125

2014

Link zum Volltext

Verfügbarkeit prüfen

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

Clinical cancer research, 2010-11, Vol.16 (22), p.5581-5590

2010

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Clinical cancer research, 2019-10, Vol.25 (19), p.5832-5842

2019

Link zum Volltext

Verfügbarkeit prüfen

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Cancer, 2012-09, Vol.118 (18), p.4502-4511

2012

Link zum Volltext

Verfügbarkeit prüfen

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Journal of thoracic oncology, 2016-08, Vol.11 (8), p.1293-1304

2016

Link zum Volltext

Verfügbarkeit prüfen

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

PloS one, 2010-11, Vol.5 (11), p.e14117

2010

Link zum Volltext

Verfügbarkeit prüfen

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (3), p.546-556

2019

Link zum Volltext

Verfügbarkeit prüfen

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Cancer discovery, 2019-03, Vol.9 (3), p.384-395

2019

Link zum Volltext

Verfügbarkeit prüfen

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Molecular cancer therapeutics, 2017-08, Vol.16 (8), p.1623-1633

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 207

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(195)

Publikationsform

Sprache

Englisch
(207)
Japanisch
(50)
Spanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(124)
Life Sciences & Biomedicine
(121)
Humans
(108)
Oncology
(98)
Lung Neoplasms - Drug Therapy
(55)
Lung Neoplasms - Genetics
(50)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(48)
Carcinoma, Non-Small-Cell Lung - Genetics
(44)
Male
(44)
Female
(42)
Middle Aged
(39)
Lung Cancer
(37)
Mutation
(37)
Lung Neoplasms - Pathology
(36)
Carcinoma, Non-Small-Cell Lung - Pathology
(30)
Aged
(29)
Respiratory System
(29)
Adult
(28)
Protein Kinase Inhibitors - Therapeutic Use
(28)
Tumors
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Pathways: ROS1 Fusion Proteins in Cancer

Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC

TRKing down an old oncogene in a new era of targeted therapy

Treating ALK-positive lung cancer--early successes and future challenges

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib

Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples

Resistance Mechanisms to Targeted Therapies in ROS1 + and ALK + Non-small Cell Lung Cancer

Management of Brain Metastases in ALK-Positive Non-Small-Cell Lung Cancer

Identifying and Targeting ROS1 Gene Fusions in Non―Small Cell Lung Cancer

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non-Small Cell Lung Cancer

Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes

Targeted Therapies in Non-Small Cell Lung Cancer: Emerging Oncogene Targets Following the Success of Epidermal Growth Factor Receptor

Optimizing the Detection of Lung Cancer Patients Harboring Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements Potentially Suitable for ALK Inhibitor Treatment

Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

Identifying the Appropriate FISH Criteria for Defining MET Copy Number–Driven Lung Adenocarcinoma through Oncogene Overlap Analysis

Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins

A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling

Suchergebnisse filtern